Skip to content

To observe the clinical effect of fire dragon pot combined with moxibustion on lower limb numbness in patients with ischemic stroke

To observe the clinical effect of fire dragon pot combined with moxibustion on lower limb numbness in patients with ischemic stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000255
Enrollment
Unknown
Registered
2024-08-17
Start date
2023-12-09
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Control group:Rosuvastatin calcium tablets 5-10 mg each time, oral after dinner, once a day
Aspirin enteric-coated tablets 100 mg each time, oral before lunch, once a day
Mecobalamin injection 0.5 mg each time was added to 5% glucose injection 250mL by intravenous drip, once a day. Diet (pay attention to diet, pay attention to control blood pressure, blood lipids, bloo
Experimental Group:On the basis of the control group, comprehensive moxibustion with fire dragon pot was given

Sponsors

1076 Yuhua Road, Chenggong District, Kunming City, Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) meet the above diagnostic criteria of traditional Chinese and western medicine; (2) Qi deficiency and blood stasis type according to the syndrome diagnostic criteria; (3) patients with unilateral lower limb numbness after onset, with or without abnormal sensations such as heaviness and electric shock; (4) age 40-80 years old, disease duration within 2 weeks to 6 months; (5) patients without moxa smoke allergy, scar constitution and coagulation dysfunction; (6) The patient was in stable condition, conscious, with good cognition and expression ability. He agreed to cooperate with the treatment and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) numbness of limbs caused by non-cerebrovascular diseases or other diseases, such as neck and lumbar diseases, diabetes, vitamin deficiency, metabolic disorders, infection, poisoning, autonomic nerve dysfunction and other diseases; (2) acute stroke or combined with serious life-threatening diseases; (3) visual impairment, confusion, speech difficulties and other obstacles to cooperate with treatment and evaluation; (4) patients receiving treatment in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Levi sensory neurotoxicity grading criteria and visual analogue scale (VAS) score;Clinical efficacy;

Secondary

MeasureTime frame
Barthel index rating scale score;Fugl-Meyer lower extremity sensory impairment score;

Countries

China

Contacts

Public ContactXiaoying He

Yunnan University of Traditional Chinese Medicine

2069642268@qq.com13769853241

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026